Colgate-Palmolive Company $CL Stock Holdings Lowered by Cidel Asset Management Inc.

Cidel Asset Management Inc. reduced its holdings in Colgate-Palmolive Company (NYSE:CL) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 314,644 shares of the company’s stock after selling 14,416 shares during the quarter. Colgate-Palmolive accounts for 1.4% of Cidel Asset Management Inc.’s portfolio, making the stock its 21st largest position. Cidel Asset Management Inc.’s holdings in Colgate-Palmolive were worth $25,153,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CL. Brighton Jones LLC raised its position in Colgate-Palmolive by 4.4% in the fourth quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock worth $962,000 after acquiring an additional 450 shares in the last quarter. Woodline Partners LP raised its position in Colgate-Palmolive by 76.3% during the first quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock valued at $4,344,000 after buying an additional 20,062 shares during the period. Mutual Advisors LLC boosted its holdings in shares of Colgate-Palmolive by 5.1% during the second quarter. Mutual Advisors LLC now owns 8,265 shares of the company’s stock worth $727,000 after purchasing an additional 401 shares during the period. Stratos Wealth Advisors LLC purchased a new position in shares of Colgate-Palmolive during the 2nd quarter valued at $262,000. Finally, Arista Wealth Management LLC acquired a new position in Colgate-Palmolive in the second quarter worth approximately $571,000. 80.41% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Sally Massey sold 15,851 shares of the company’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $95.03, for a total transaction of $1,506,320.53. Following the completion of the sale, the insider directly owned 13,751 shares in the company, valued at $1,306,757.53. This represents a 53.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stanley J. Sutula III sold 97,843 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $94.27, for a total transaction of $9,223,659.61. Following the completion of the transaction, the chief financial officer directly owned 55,310 shares of the company’s stock, valued at $5,214,073.70. This trade represents a 63.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 184,683 shares of company stock valued at $17,486,693 in the last three months. Company insiders own 0.34% of the company’s stock.

Key Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Jim Cramer highlighted Colgate’s strong growth on his show, a high-visibility endorsement that can boost investor sentiment and trading interest. Colgate (CL) had great growth, says Jim Cramer
• Positive Sentiment: Zacks Research raised several near‑term and longer‑term EPS estimates (including FY2026, FY2027 and Q4 updates) — a signal of improving analyst expectations that supports the stock’s upside. Market summary with Zacks note: Colgate-Palmolive (CL) — MarketBeat summary
• Positive Sentiment: Recent quarterly results beat estimates (Q4 EPS and revenue topped consensus) and the company recently paid its regular quarterly dividend — both reinforce Colgate’s cash-generation and income-profile that investors prize in staples. Full company/analyst roundup: Colgate-Palmolive (CL) — MarketBeat summary
• Neutral Sentiment: Zacks issued a mix of small raises and cuts across individual quarters (some Q1–Q3 2026/2027 estimates were trimmed while other quarters were nudged higher). The net effect is modest — watch upcoming quarterly cadence rather than reacting to isolated quarter tweaks. Source: MarketBeat/Zacks summary: Colgate-Palmolive (CL) — MarketBeat summary
• Negative Sentiment: Significant insider selling by the COO, Panagiotis Tsourapas — 35,000 shares sold Feb. 11 and another 15,000 on Feb. 12 (disclosures show a large reduction in his holdings). Large exec sales can be perceived negatively by investors even if they’re for diversification or liquidity reasons. Colgate-Palmolive (NYSE:CL) COO Sells $1,467,150.00 in Stock
• Negative Sentiment: Another insider (John Hazlin) recently sold ~20,989 shares; multiple insider sales in a short span increase perceived governance/insider-conviction risk. SEC filing and trade details: SEC Filing — Insider Sales

Wall Street Analyst Weigh In

A number of analysts have weighed in on CL shares. JPMorgan Chase & Co. boosted their price target on Colgate-Palmolive from $93.00 to $97.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Piper Sandler upped their price objective on shares of Colgate-Palmolive from $88.00 to $96.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Citigroup raised their target price on Colgate-Palmolive from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. UBS Group increased their target price on Colgate-Palmolive from $90.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, January 14th. Finally, Raymond James Financial cut their price target on shares of Colgate-Palmolive from $105.00 to $95.00 and set an “outperform” rating for the company in a report on Monday, October 20th. Eleven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.38.

Colgate-Palmolive Price Performance

NYSE CL opened at $96.61 on Friday. Colgate-Palmolive Company has a 12-month low of $74.54 and a 12-month high of $100.18. The company has a market capitalization of $77.87 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 4.36 and a beta of 0.29. The company has a quick ratio of 0.27, a current ratio of 0.42 and a debt-to-equity ratio of 5.90. The firm’s 50 day moving average is $83.80 and its 200-day moving average is $81.87.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.04. The firm had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.13 billion. Colgate-Palmolive had a net margin of 10.45% and a return on equity of 353.72%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.91 earnings per share. Equities research analysts anticipate that Colgate-Palmolive Company will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Wednesday, January 21st were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, January 21st. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 79.39%.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.